Insulet, Uber And A Financial Stock On CNBC's 'Final Trades'

Author: Avi Kapoor | November 05, 2025 08:26am

On CNBC's “Halftime Report Final Trades,” Joseph Terranova, senior managing director at Virtus Investment Partners, named Insulet Corporation (NASDAQ:PODD), a maker of wearable devices for insulin management, as his final trade.

Lending support to his choice, Stifel analyst Jonathan Block, on Oct. 21, reinstated Insulet with a Buy and announced a $370 price target.

Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, said he is staying long on Uber Technologies, Inc. (NYSE:UBER).

The company, on Tuesday, reported a 20% year-over-year (Y/Y) revenue growth to $13.47 billion, surpassing the analyst consensus estimate of $13.28 billion. Uber reported adjusted EPS of 81 cents, which beat the analyst consensus estimate of 69 cents.

Don't forget to check out our premarket coverage here

Jim Lebenthal, partner at Cerity Partners, praised Apollo Global Management‘s (NYSE:APO) earnings report.

The firm, on Tuesday, reported better-than-expected adjusted earnings per share results. Apollo reported adjusted earnings per share of $2.17, beating the consensus estimate of $1.91. In addition, the company reported sales of $9.82 billion, beating the consensus estimate of $5.02 billion.

Price Action:

• Insulet shares rose 0.5% to close at $320.27 on Tuesday.
• Uber shares dipped 5.1% to close at $94.67 during the session.
• Apollo Global Management shares gained 5.3% to close at $130.51 on Tuesday.

Check This Out:

• Top 2 Industrials Stocks You May Want To Dump This Quarter

Image: Courtesy of Insulet

Posted In: APO PODD UBER